Children with growth hormone deficiency are currently treated with daily injections of recombinant growth hormone. The burden of 365 injections per year and cold chain storage causes a poor medication adherence. Long-acting growth hormones were developed to decrease injection frequency and therefore to promote a better therapeutic compliance. This paper discusses what long-acting drugs are currently on the market and their mechanism of action, and identifies the patient groups that may benefit from them.

I LAGH (ormoni della crescita long-acting): cosa sono e a chi proporli?

Rodaro, Chiara;Tornese, Gianluca
2024-01-01

Abstract

Children with growth hormone deficiency are currently treated with daily injections of recombinant growth hormone. The burden of 365 injections per year and cold chain storage causes a poor medication adherence. Long-acting growth hormones were developed to decrease injection frequency and therefore to promote a better therapeutic compliance. This paper discusses what long-acting drugs are currently on the market and their mechanism of action, and identifies the patient groups that may benefit from them.
File in questo prodotto:
File Dimensione Formato  
MedicoeBambino_2406_371.pdf

Accesso chiuso

Tipologia: Documento in Versione Editoriale
Licenza: Digital Rights Management non definito
Dimensione 78.78 kB
Formato Adobe PDF
78.78 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11368/3078658
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact